

## Extension Seminar in Cardiology

### Preliminary program

*This seminar will be delivered by a combination of a 6-week self-paced learning package followed by a live one-day seminar*

**Self-paced learning package:** available from Friday 2 May 2025

The self-paced learning package comprises approximately 4 hours of learning materials. The self-paced learning package materials must be completed prior to attending the live virtual seminar.

Area	Topics covered	Learning objectives	Presenters
<b>Valvular disease</b>	Anatomy (30 mins) Physiology (30 mins) TAVI (30 mins)	<p><b>Aortic Valve Disease</b></p> <ul style="list-style-type: none"> <li>• Overview the anatomy and physiology of the aortic valve</li> <li>• Explain the symptoms related to a regurgitant valve and to a stenosed aortic valve.</li> <li>• Describe the implications of the gradient pressures and their impact on symptoms</li> <li>• Explain the medical therapy required for the patient with a stenosed aortic valve, including: <ul style="list-style-type: none"> <li>○ Ischaemia management</li> <li>○ Atrial fibrillation management</li> <li>○ Fluid management</li> </ul> </li> <li>• Explain the surgical interventions available (replacement and TAVI replacement) to correct the aortic valve</li> </ul> <p><b>Mitral Valve Disease</b></p> <ul style="list-style-type: none"> <li>• Overview the anatomy and physiology of the mitral valve and the structural apparatus attached</li> <li>• Explain the causes of a regurgitant mitral valve and the implications for the patient</li> <li>• Describe the surgical corrections available for mitral valve disease and the implications for the patient and the medications required, including: <ul style="list-style-type: none"> <li>○ Anticoagulation</li> <li>○ Heart failure therapies</li> </ul> </li> <li>• Explain the implications to the patient of repair vs replacement of the mitral valve.</li> </ul>	
<b>Aortic stenosis</b>	Self-directed case study (30 mins)	<b>To be confirmed</b>	
<b>Infiltrative cardio-myopathies</b>	Amyloidosis diagnostics (30 mins) Pharmacological therapy (30 mins)	<ul style="list-style-type: none"> <li>• Differentiate between the two forms of cardiac amyloidosis</li> <li>• Identify signs and symptoms of cardiac amyloidosis</li> </ul>	

SEMINAR

		<ul style="list-style-type: none"> <li>• Describe the diagnostics involved in cardiac amyloidosis             <ul style="list-style-type: none"> <li>• Bone scan</li> <li>• Echocardiography</li> <li>• Cardiac MRI</li> <li>• Biopsy</li> </ul> </li> <li>• Explain the pharmacological therapy (mechanism, impact on symptoms and survival) for transthyretin amyloidosis, including:             <ul style="list-style-type: none"> <li>○ Managing the HFpEF symptoms</li> <li>○ Pitfalls of using ACE inhibitors, ARB's and sacubitril.</li> <li>○ Tafamidis</li> </ul> </li> <li>• Explain how to manage decline in renal function in these patients</li> </ul>	
<p><b>Hypertrophic Cardio-myopathies</b></p>	<p>Genetics (30 mins) Diagnostics (30 mins)</p>	<ul style="list-style-type: none"> <li>• Describe the diagnostics involved in hypertrophic cardiomyopathies:             <ul style="list-style-type: none"> <li>○ Echocardiography</li> <li>○ Cardiac MRI</li> <li>○ Family history</li> <li>○ Genetics of the condition</li> </ul> </li> <li>• Outline the symptoms the patient will describe</li> <li>• Explain the management of arrhythmia in this patient group:             <ul style="list-style-type: none"> <li>○ Amiodarone use plus or minus betablockade</li> <li>○ Use of Implantable defibrillators</li> </ul> </li> <li>• Describe the surgical and invasive treatment options available:             <ul style="list-style-type: none"> <li>• Intracoronary alcohol</li> <li>• Surgical debulking</li> </ul> </li> <li>• Explain the use of targeted pharmacological treatment:             <ul style="list-style-type: none"> <li>○ Disopyramide</li> <li>○ Verapamil</li> <li>○ Mavacamten dosing</li> </ul> </li> <li>• Explain the role of echocardiogram monitoring for dose adjustment</li> <li>• Overview the management of associated drug interactions</li> <li>• Identify emerging therapies for treatment and management</li> </ul>	

## Extension Seminar in Cardiology

### Preliminary Program

**Live virtual seminar: Saturday 2 June 2025**

*All times are listed in AEDT. The below may be subject to change*

Time (AEST)	Session
0945-1000	Online login and registration available
1000-1030	<b>Welcome, housekeeping, &amp; review of online learning content</b> <b>Garth Birdsey</b> , <i>Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic</i>
1030-1115	<b>Presentation: Surgical management of heart valve disease</b>
1115-1130	Break
1130-1215	<b>Case session: Atrial fibrillation in valvular disease</b>
1215-1245	Break
1245-1330	<b>Case session: Cardiac sarcoidosis or Amyloidosis</b>
1330-1345	Break
1345-1430	<b>Case study: HCM</b>
1430-1515	<b>Q&amp;A</b> <b>Garth Birdsey</b> , <i>Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic</i>
1515	Seminar close

*Please note presentation recordings will not be available from the live day seminar.*